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Case–control, kin-cohort and meta-analyses provide no support
for STK15 F31I as a low penetrance colorectal cancer allele
EL Webb
1, MF Rudd
1 and RS Houlston*,1
1Section of Cancer Genetics, Institute of Cancer Research, Surrey, UK
Recently, homozygosity for T91A single-nucleotide polymorphism (SNP) in the serine/threonine kinase (STK15) gene, which
generates the substitution F31I has been proposed to increase the risk of a number of tumours including colorectal cancer (CRC). To
further evaluate the relationship between STK15 F31I and risk of CRC, we genotyped 2558 CRC cases and 2680 controls for this
polymorphism. We found no evidence that homozygosity for the STK15 31I genotype confers an increased risk of CRC (odds
ratio¼0.95, 95% confidence interval (CI): 0.74–1.24). We also conducted a kin-cohort analysis to assess risk among first-degree
relatives of the CRC cases. The hazard ratio for I/I homozygotes compared to F/F homozygotes was 1.65 (95% CI: 0.39–3.17). A
meta-analysis of our case–control data and three previous studies also provided no evidence of an elevated risk of CRC associated
with homozygosity. These data provide no support for the hypothesis that sequence variation in STK15 defined by SNP F31I per se
confers an elevated risk of CRC.
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Serine/threonine kinase (STK15; MIM:603072) is a regulator of
mitotic chromosomal segregation (Dutertre et al, 2002) and plays a
role in the development of malignancy (Bischoff et al, 1998; Zhou
et al, 1998; Ewart-Toland et al, 2003). Recently, the T91A single-
nucleotide polymorphism (SNP) in STK15, which generates the
substitution F31I, and has been reported to influence genomic
instability (Ewart-Toland et al, 2003; Kimura et al, 2005), has been
proposed as a low penetrance variant for a number of tumours
including colorectal cancer (CRC) (Ewart-Toland et al, 2003, 2005).
To further evaluate the relationship between STK15 F31I and risk
of CRC, we genotyped 2558 CRC cases and 2680 controls for this
polymorphism. We also conducted a kin-cohort analysis to assess
risk among first-degree relatives of the CRC cases.
MATERIALS AND METHODS
Unselected CRC cases with histologically confirmed colorectal
adenocarcinomas (1471 men; 1087 women; mean age at diagnosis
61 years; standard deviation (s.d.)711.4) were ascertained through
over 100 centres in the UK. Detailed family histories were obtained
from cases by previously validated questionnaire. Controls (836
men; 1844 women; mean age 59 years; s.d.710.9) were the spouses
or friends of patients with malignancies ascertained as part of
ongoing National Cancer Research Network genetic epidemiologi-
cal studies (1999–2004; n¼1067), the Royal Marsden Hospital
Trust/Institute of Cancer Research Family History and DNA
Registry (1999–2004; n¼1021) and UK Study of Breast Cancer
Genetics (1999–2004; n¼592) all established within the UK. None
of the controls had a personal history of malignancy at time of
ascertainment. As we are not seeking to evaluate environmental
interactive effects, the theoretical possibility of ‘overmatching’ on
environmental factors by using spouse and friend controls is
unlikely to impact on study findings. All cases and controls were
British Caucasians, and there were no obvious differences in the
demography of cases and controls in terms of place of residence
within the UK. Blood samples were obtained with informed
consent and ethical review board approval in accordance with the
tenets of the Declaration of Helsinki.
Analysis of STK15 F31I was undertaken as part of our ongoing
analyses to identify low penetrance alleles based on the National
Study of Colorectal Cancer Genetics Trial (2004). DNA was
extracted from blood samples using conventional methodologies
and quantified using PicoGreen (Invitrogen, Carlsbad, CA, USA).
Genotyping was performed using the Illumina Sentrix Bead Array
system according to the manufacturer’s protocols. Further
information on the assays is available on request.
Risks were estimated by odds ratios (ORs) using unconditional
logistic regression, and associated 95% confidence intervals (CIs)
computed. Meta-analysis of this and other published studies was
conducted using standard methods for combining estimates of
ORs based on the weighted sum of the log estimates with the
inverse of the variance of the estimate of the weight. Cochran’s Q
statistic (Cochran, 1954) to test for heterogeneity and the I
2
statistic (Higgins et al, 2003) to quantify the proportion of the total
variation owing to heterogeneity were calculated. To incorporate
within-study and between-study variability, we used DerSimioian
and Laird’s method (DerSimonian and Laird, 1986) for calculating
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computations were undertaken in STATA (version 8.2, Stata
Corporation, College Station, TX, USA).
We also performed a kin-cohort analysis to compare the CRC
risk in first-degree relatives of STK15 I homozygotes with that in
first-degree relatives of F homozygotes. Proband genotypes and the
SNP allele frequency were used to infer genotypes of relatives. Age-
specific cumulative CRC distributions in first-degree relatives were
estimated using a marginal likelihood approach (Chatterjee and
Wacholder, 2001), implemented in MatLab version 7.0.1 (Math-
Works, Natick, MA, USA). Bootstrap estimates for the hazard ratio
(HR) were then computed, using 1000 resamples of the data, and
used to generate a 95% CI.
RESULTS
There was no evidence of population stratification as the genotype
distribution of F31I in controls satisfied Hardy–Weinberg
equilibrium (P¼0.63). We found no evidence that homozygosity
for the STK15 I genotype confers an increased risk of CRC (cases:
F/F¼1564, F/I¼880 and I/I¼114; controls: F/F¼1667, F/I¼888,
I/I¼125; OR¼0.95, 95% CI: 0.74–1.24). As there is no a priori
reason to assume a recessive model of CRC susceptibility, we also
computed the risk associated with heterozygotes using the F/F
genotype as the reference group. The OR under this model was
1.06 (95% CI: 0.94–1.19).
Three other studies have compared the frequency of STK15 F31I
genotypes in cases and controls (Ewart-Toland et al, 2005); two
based on predominantly Caucasians and one based on Han
Chinese. Figure 1 shows estimates of the recessive homozygote risk
from this study and from published studies. The study based on
Han Chinese was alone in showing a significant positive
association and was the only study where results differed
significantly from our analysis. The pooled OR estimate was 1.31
(95% CI: 0.96–1.78); interpretation of this is not, however, clear as
the estimates in different studies are clearly heterogeneous
(Cochran’s Q¼8.21, P¼0.042, I
2¼64%). Restricting the meta-
analysis to the three studies based on Caucasians, between-study
heterogeneity was less evident (Cochran’s Q¼3.1, P¼0.21,
I
2¼35%). The pooled estimate of the OR was 1.15 (95% CI:
0.87–1.51).
The 2558 cases reported a total of 14649 first-degree relatives of
whom 445 (3.0%) had been diagnosed with CRC. The HR for I/I
homozygotes compared to F/F homozygotes was 1.65 (95% CI:
0.39–3.17).
DISCUSSION
It has previously been proposed that the STK15 F31I polymorph-
ism confers a 1.5-fold increase in risk of CRC (Ewart-Toland
et al, 2005). Even though our study had over 90% power to detect
this magnitude of increased risk at significance level 5%, we
found no evidence to support the hypothesis that F31I is a
CRC susceptibility allele. Moreover, the meta-analysis we
conducted of 9309 subjects also provides no evidence of an
increased risk. There was, however, a high degree of variation in
the ORs estimated by individual studies. The frequency of
the I-allele is markedly different in Caucasians and Han Chinese
(21 and 61% respectively), thus it may be inappropriate to
regard the different ethnic groups as genetically similar. As the
frequency of genotypes in controls in the other studies are
not significantly different from those expected, there is little
evidence that overt population stratification underpins study
heterogeneity. Although there is some data to suggest that F31I
has functional cellular consequences (Ewart-Toland et al,
2003; Kimura et al, 2005), direct causality has not been
demonstrated. It is possible that population-specific linkage
disequilibrium with another functional variant could be operating.
Some support for this is provided by the observation of Lo et al
(2005) that in the Taiwanese population the risk of breast
cancer associated with F31I is mediated through an extended
haplotype. Finally, as with all association studies a simple but
unattractive explanation for the observed heterogeneity is
publication bias. In summary, collectively these data provide no
support for the hypothesis that sequence variation in STK15
defined by the nonsynonymous SNP F31I per se confers an
elevated risk of CRC.
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Figure 1 Forest plot of the risk of CRC associated with STK15-I/I
homozygosity from comparison of I/I vs I/F and F/F genotypes combined for
(A) all studies and (B) all Caucasian studies. Shaded squares denote ORs,
with their size being proportional to the inverse variance of the study-
specific estimate. Horizontal lines represent 95% CIs. The diamond denotes
the combined random effects estimate and its associated 95% CI. The
vertical line indicates the null effect (OR¼1.0).
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